10-K: Ludwig Enterprises, Inc. Reports Annual Results for 2024, Focuses on mRNA Technology

Ludwig Enterprises, Inc. reports its annual results for 2024, highlighting its focus on developing mRNA-based genomic technology for early detection of inflammatory diseases.

Summary

• Ludwig Enterprises, Inc. reported a net loss of $3,016,884 for the year ended December 31, 2024.
• The company is focused on developing mRNA-based genetic markers to measure inflammation and related diseases.
• They are developing Revealia Home Test Kits that use mRNA genetic indices to measure cytokines and chemokines.
• The company plans to conduct clinical trials for urothelial carcinoma of the bladder, preeclampsia, and cardiovascular/heart diseases, each estimated to cost $1,250,000.
• Ludwig Enterprises is pursuing Laboratory Developed Test (LDT) classification for its testing kits.
• The company had a working capital deficit of $2,378,145 as of December 31, 2024.
• The company expects revenues from sales of its planned products will begin during the third quarter of 2025, assuming it is able to obtain needed funding of approximately $1,500,000.
• The company sold its wholly-owned subsidiary, Exousia AI, Inc., to Marijuana Inc. (MAJI) for 10,000 Series B Convertible Stock and a $100,000 Secured Promissory Note.
• The company has filed three pending patent applications related to its mRNA technology.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is pursuing innovative technology and has plans for future growth, the significant net loss, working capital deficit, and dependence on raising additional capital raise concerns about its financial stability.

Positives

• The company is developing innovative mRNA-based technology with potential for early disease detection.
• The company has filed three pending patent applications to protect its intellectual property.
• The company is planning clinical trials to validate its technology.
• The company expects revenues from sales of its planned products will begin during the third quarter of 2025, assuming it is able to obtain needed funding of approximately $1,500,000.

Negatives

• The company reported a significant net loss of $3,016,884 for the year ended December 31, 2024.
• The company has a substantial accumulated deficit of $7,259,366.
• The company has a working capital deficit of $2,378,145 as of December 31, 2024.
• The company has not yet derived revenues from its operations.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company may face challenges in securing additional funding to complete planned research studies.
• The company's products may be subject to regulatory scrutiny and may not be classified as Laboratory Developed Tests (LDTs).
• The company may face competition from existing direct-to-consumer DNA genetic testing companies.
• The company's success depends on its ability to market and distribute its products effectively.
• The company's internal control over financial reporting was not effective as of December 31, 2024.

Future Outlook

The company expects revenues from sales of its planned products will begin during the third quarter of 2025, assuming it is able to obtain needed funding of approximately $1,500,000. The company intends to conduct clinical trials for urothelial carcinoma of the bladder, preeclampsia, and cardiovascular/heart diseases.

Management Comments

• We believe the future of healthcare will focus on personalized medicine that is preventative, rather than reactive, and we can be at the front of this revolution.
• We are of the opinion, and believe that many others share our sentiment, that the healthcare system, as it is currently structured, can be improved.

Industry Context

The company operates in the genomic technology and health-related sector, focusing on mRNA-based diagnostics. The global direct-to-consumer Genetic Testing Market is positioned to grow by $1.38 billion USD through 2025, with a compound annual growth rate of 16.73%.

Comparison to Industry Standards

• The company believes there are few existing comparable competitors with an mRNA focus.
• The company feels the closest competitors are companies that engage in direct-to-consumer DNA genetic testing, such as 23andME Inc., Alpha Laboratories Ltd., and Centrillion Technology Holding Ltd.
• The company believes that a primary difference between us and any of the comparable companies described above is that we are focused on mRNA, while they focus on DNA.

Management Changes

Corporate Governance

Related Party Transactions

• The manager of Barranquilla Investments, LLC is Marvin S. Hausman, M.D., our Chief Executive Officer. Dr. Hausman has the sole voting and dispositive control over the shares held by Barranquilla Investments, LLC.
• Carl Rubin is the Chief Executive Officer of Homeopathic Partners, Inc. Mr. Rubin has the sole voting and dispositive control over the shares held by Homeopathic Partners, Inc.
• Corain McGinn is the Chief Executive Officer of Vasaio Capital, Inc. Mr. McGinn has the sole voting and dispositive control over the shares held by Vasaio Capital, Inc.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees' job security is dependent on the company's ability to secure funding and achieve profitability.
• Customers may benefit from innovative diagnostic products if the company successfully develops and commercializes them.
• Suppliers and creditors face risks associated with the company's financial instability.

Next Steps

• The company plans to commence clinical trials for urothelial carcinoma of the bladder, preeclampsia, and cardiovascular/heart diseases.
• The company intends to launch and market its testing kits as a Laboratory Developed Test (LDT).
• The company plans to engage social media marketing such as Facebook, Instagram and Twitter to reach potential customers.

Key Dates

Keywords

mRNA, genomic technology, inflammation, biomarkers, clinical trials, LDT, Revealia, genetic testing, healthcare, diagnostics